The month of September will herald the first fully in-person US Food and Drug Administration advisory committee meeting on a new drug application since the start of the COVID-19 pandemic in 2020.
Back To White Oak: US FDA Adcomms Go Fully In-Person, Starting With Antimicrobials Panel
The 9 September meeting on Iterum Therapeutics' oral sulopenem product for uncomplicated urinary tract infections marks the first fully in-person advisory committee drug review since the COVID-19 pandemic hit in early 2020.
